Table 1.

Demographic data and underlying diseases of the study population

	Classification according to revised EORTC/MSG criteria			Classification according to Blot criteria
	Probable or proven IPA (n=13)	No evidence for IPA (n=65)	Possible IPA (n=4)	Putative/Proven IPA (n=26)
Female (n, %)	5 (38%)	26 (40%)	1 (25%)	8 (31%)
Age, years (median, range)	58 (41–79)	56 (19–80)	66 (49–67)	57 (19–79)
Primary Underlying diseases / conditions (n, %)
Lung Transplant	2 (15%)	19 (29%)	3 (75%)	7 (27%)
Other Transplant	1 (8%)	2 (3%)	-	1 (4%)
Oncological malignancy	1 (8%)	5 (8%)	1 (25%)	2 (8%)
Liver Cirrhosis	-	5 (8%)	-	3 (12%)
Interstitial Lung Disease	1 (8%)	5 (8%)	-	2 (8%)
Rheumatoid/autoimmune diseases with lung involvement	1 (8%)	4 (6%)	-	1 (4%)
HIV/AIDS	1 (8%)	3 (5%)	-	2 (8%)
Tuberculosis	1 (8%)	1 (2%)	-	-
Asthma	-	3 (5%)	-	1 (4%)
Cystic fibrosis	-	3 (5%)	-	-
Others	1 (8%)	4 (6%)	-	2 (8%)
ICU COPD	1 (8%)	3 (5%)	-	1 (4%)
ICU Septic Shock	3 (23%)	1 (2%)	-	3 (12%)
ICU others	-	7 (11%)	-	1 (4%)
Overall Mortality 30-days	2 (15%)	14 (22%)	1 (25%)	8 (31%)
Overall Mortality 90-days	3/12 (25%)	14/63 (22%)	1 (25%)	9/25 (36%)

^*= In one case of probable IPA and putative IPA, an additional BALF samples drawn 14 days earlier was available (only the later sample was included in the analysis). The patient fulfilled probable IPA criteria throughout the 14days. Patients first BALF sample (not included in this analysis) resulted positive for GM (2.38 ODI), grew Aspergillus terreus in culture and gave positive results with both the LFA and LFD, but the patient did not fulfill criteria of putative IPA according to Blot because of lack of typical symptoms. Two weeks later, at the time of the second BALF sample, this patient had still positive GM, positive LFD and positive LFA, negative culture, but symptoms as defined by Blot criteria and therefore fulfilled putative IPA criteria.